Luz Reyes, Zheng-Yu Wang, Jose Estrada, Christopher Burlak, Victor Novara Gennuso, Sam Ho, Matt Tector, Alfred Joseph Tector
{"title":"Non-Classical Swine Leukocyte Antigens SLA-6, -7, and -8, Are Xenoantigens for Some Waitlisted Patients.","authors":"Luz Reyes, Zheng-Yu Wang, Jose Estrada, Christopher Burlak, Victor Novara Gennuso, Sam Ho, Matt Tector, Alfred Joseph Tector","doi":"10.1111/xen.12872","DOIUrl":null,"url":null,"abstract":"<p><p>Attack of donor tissues by pre-formed anti-pig antibodies is well known to cause graft failure in xenotransplantation. Genetic engineering of porcine donors to eliminate targets of these pre-formed antibodies coupled with advances in immunosuppressive medicines have now made it possible to achieve extended survival in the pre-clinical pig-to-non-human primate model. Despite these improvements, antibodies remain a risk over the lifetime of the transplant, and many patients continue to have pre-formed donor-specific antibodies even to highly engineered pigs. While therapeutics exist that can help mitigate the detrimental effects of antibodies, they act broadly potentially dampening beneficial immunity. Identifying additional xenoantigens may enable more targeted approaches, such as gene editing, to overcome these challenges by further eliminating antibody targets on donor tissue. Because we have found that classical class I swine leukocyte antigens are targets of human antibodies, we now examine whether related pig proteins may also be targeted by human antibodies. We show here that non-classical class I swine leukocyte proteins (SLA-6, -7, -8) can be expressed at the surface of mammalian cells and act as antibody targets.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/xen.12872","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
Abstract
Attack of donor tissues by pre-formed anti-pig antibodies is well known to cause graft failure in xenotransplantation. Genetic engineering of porcine donors to eliminate targets of these pre-formed antibodies coupled with advances in immunosuppressive medicines have now made it possible to achieve extended survival in the pre-clinical pig-to-non-human primate model. Despite these improvements, antibodies remain a risk over the lifetime of the transplant, and many patients continue to have pre-formed donor-specific antibodies even to highly engineered pigs. While therapeutics exist that can help mitigate the detrimental effects of antibodies, they act broadly potentially dampening beneficial immunity. Identifying additional xenoantigens may enable more targeted approaches, such as gene editing, to overcome these challenges by further eliminating antibody targets on donor tissue. Because we have found that classical class I swine leukocyte antigens are targets of human antibodies, we now examine whether related pig proteins may also be targeted by human antibodies. We show here that non-classical class I swine leukocyte proteins (SLA-6, -7, -8) can be expressed at the surface of mammalian cells and act as antibody targets.
众所周知,在异种移植中,预先形成的抗猪抗体会攻击供体组织,导致移植失败。通过对猪供体进行基因工程改造以消除这些预先形成的抗体的靶点,再加上免疫抑制药物的进步,现在已经可以延长临床前猪到非人灵长类动物模型的存活时间。尽管取得了这些进步,但在移植的整个生命周期中,抗体仍然是一个风险,即使是高度工程化的猪,许多患者仍然会有预先形成的捐献者特异性抗体。虽然现有疗法可以帮助减轻抗体的有害影响,但它们的作用范围很广,可能会抑制有益的免疫力。识别更多的异抗原可能使基因编辑等更有针对性的方法成为可能,通过进一步消除供体组织上的抗体靶点来克服这些挑战。由于我们发现经典的 I 类猪白细胞抗原是人类抗体的靶标,我们现在研究相关的猪蛋白是否也会成为人类抗体的靶标。我们在此证明,非经典的 I 类猪白细胞蛋白(SLA-6、-7、-8)可以在哺乳动物细胞表面表达,并成为抗体靶点。